tract carcinoma (Nakanishi et al, 1998) and glioma (Hsu et al, 1995) . However, in non-small cell lung cancer, neither ELISA nor IHC determinations for PAI-1 and uPAR were related to survival (Pappot et al, 1997) .
Observations in experimental systems and on clinical material also pointed to a role for proteases in melanocytic tumour progression (see reviews by de Vries et al, 1996; Mueller, 1996; Ferrier et al, 1998b) . The presence of PA components in common naevi, dysplastic naevi and malignant melanoma has earlier been studied by us (de Vries et al, 1994) and others (Delbaldo et al, 1994) using IHC, in situ hybridization and in situ zymography. Both found an increase of expression with higher grade of disease, and concluded that components of the PA system are markers for progression in melanocytic lesions. Also in uveal melanoma, high uPA expression was shown to be associated with progression of disease (de Vries et al, 1995) .
In the present study we investigated the potential of uPA, tPA, PAI-1, PAI-2 and uPAR expression to be markers for prognosis in primary melanoma. Therefore, IHC staining was performed on 214 primary cutaneous melanomas from clinical stage II (T 3-4 N 0 M 0 , American Joint Committee on Cancer) patients with well documented follow-up. Expression levels were correlated to: One tPA score was missing for a young female with a nodular melanoma on the leg, Breslow thickness ≤2 mm, Clark level 3, ulceration present, treated by wide excision, no elective lymph-node dissection. Follow-up revealed a recurrence, no distant metastasis or death.
b Death cases were melanoma-related with the presence of distant metastasis in 49 cases, melanoma-independent with the presence of a distant metastasis in one case, melanoma-independent without the presence of distant metastasis in two cases and without known cause in one case disease-free interval; time to distant metastases; and overall survival. The additive value in relation to established prognostic factors was evaluated by multivariate analysis.
PATIENTS, MATERIALS AND METHODS

Patients
Two hundred and fourteen clinically stage II (T 3-4 N 0 M 0 , American Joint Committee on Cancer) patients with primary melanoma of the limb were evaluated. These patients were enrolled in an international phase III trial (no. 18832, by the European Organization for Research and Treatment of Cancer), testing the benefits of wide excision of the primary lesion plus prophylactic isolated limb perfusion with melphalan under mild hyperthermia as compared to wide excision only (Schraffordt Koops et al, 1998) . Relevant inclusion criteria were tumour localization at or distal to the middle of the thigh or upper arm and a tumour-thickness of minimally 1.5 mm (T 3-4 ) as measured by the local pathologist. In spite of the tumour thickness requirement, three lesions had a Breslow thickness below 1.5 mm, due to discrepancies between Breslow indices as measured by the first pathologist and the reviewing pathologist. Patients who had (excision) biopsy of the primary melanoma more than 6 weeks before were not eligible for participation in the trial. For the present study, Dutch participants, included between 1986 and 1993, were studied. Complete follow-up was available for all patients. For detailed patient characteristics, see Table 1 .
Tissues
Paraffin blocks were collected from 45 different departments of pathology. All tissues had been routinely processed. Of each primary melanoma, the tissue block containing the thickest portion of the lesion was selected for investigation.
Immunohistochemistry
Of each lesion 4 µm thick sections were stained with polyclonal antibodies against uPA (rabbit antibody, DAKO, Glostrup, Denmark), tPA (goat antibody no. 387, American Diagnostica, Greenwich CT, USA), PAI-1 (rabbit antibody, Department of Experimental and Chemical Endocrinology, University Medical Center St Radboud, Nijmegen, The Netherlands (Grebenschikov et al, 1997) ), PAI-2 (goat antibody, Behring Werke AG, Marburg, Germany) and uPAR (rabbit antibody, Finsen Laboratory, Copenhagen, Denmark (Rønne et al, 1995) ). To check sensitivity and specificity, stainings with other antibodies against tPA (rabbit polyclonal antibody, Department of Experimental and Chemical Endocrinology, University Medical Center St Radboud, Nijmegen, The Netherlands (Grebenschikov et al, 1997) ), PAI-2 (goat polyclonal antibody, Institute for Immunology, University Hospital Heidelberg, Germany (Schaefer et al, 1996) ) and uPAR (monoclonal antibody R2, Finsen Laboratory (Rønne et al, 1991) ), and with two other antibodies against PAI-1 (monoclonal antibody Clone 1, Monozyme, Hoersholm, Denmark; monoclonal antibody no. 380, American Diagnostica) were compared on more than 100 lesions.
IHC procedures were performed as described previously . In brief, firstly the epitopes for antibody recognition were retrieved by microwave-heating (for tPA, PAI-1 and PAI-2) or by protease digestion (for uPA and uPAR). Then, the sections were stained by a three-step procedure using biotinylated secondary antibodies in combination with alkaline phosphataselabelled avidin-biotin complex (Vector Laboratories, Burlingame CA, USA). Secondary antibodies were goat anti-rabbit immunoglobulin (Vector Laboratories), donkey anti-mouse immunoglobulin (Jackson, West Grove PA, USA), and donkey anti-goat immunoglobulin (Jackson). Vector Red (Vector Laboratories) was used as substrate to enable a clear distinction between melanin granules and staining signal.
For each component, positive and negative tissue controls , plus cancer lesions known to contain both antigen-positive and antigen-negative areas were included in each staining session. Negative staining controls were performed on a subset of antigen-positive primary melanoma lesions by replacing monoclonal antibodies with an isotype-matched irrelevant antibody (DAKGO1, Dako) and by replacing polyclonal antibodies with a primary antibody dilution which was affinity-absorbed with purified antigen and by ommission of the first antibody.
Scoring
Sections stained with polyclonal antibodies that had been used on the total group of 214 lesions were scored. First, to advance standardization, scores were assessed by joint judgement (CMF, GNPvM and DJR). After these sessions, sections were primarily scored by one observer (CMF), with joint scoring sessions for 20-30% of the sections, including random cases and all cases difficult to score. Melanoma cells were scored according to the percentage of positive cells in six categories: 0-1%, 2-5%, 6-25%, 26-50%, 51-75% or 76-100%. The distribution of melanoma cell staining was judged as: diffuse positivity, involving large continuous parts of the tumour; scattered positivity of single cells; or focal positivity of clusters of cells. In case of focal positivity, the involvement of junctional/subepidermal, central and/or frontal nests was noted. For stromal staining, the type of positive cells (fibroblast-like cells, macrophages, endothelial cells) was recorded and an estimate of the quantity of positive cells was made (0 = nil; 1 = a few cells; 2 = several clusters of cells; 3 = abundant stromal-cell positivity). Only stainings exceeding weak intensity were considered as positive.
Statistical methods
For statistical evaluation, percentage-classes reflecting the extent of tumour cell positivity were taken together to form the categories 0-5%, 6-50% and 51-100% positive tumour cells.
Associations between the extent of tumour cell positivity of different components with each other were assessed by the Spearman's rank correlation coefficient. Relation between on the one side percentage categories (0-5%, 6-50% and 51-100%) and staining patterns of the investigated components, and on the other side established prognostic variables such as Breslow thickness, ulceration and sex, were determined by Spearman's rank correlation and/or Kruskall-Wallis test.
Starting point for the different analyses was the date of registration in clinical trial no. 18832. The end-point for relapse-free interval was the date of first progression, whether local relapse, intransit metastasis, regional lymph-node metastasis or distant metastasis. The end-point for distant metastasis-free interval was the diagnosis of distant metastasis. The end-point for the duration of survival was the date of death, whatever cause. Patients still alive were considered as censored observations at the date of last follow-up. The prognostic impact of a given variable, like sex, age, site of primary melanoma, Breslow thickness, ulceration, Clark's level of invasion, type of melanoma, treatment randomized, elective lymph-node dissection, variables resulting from the IHC stainings, was first analysed univariately by estimation of the relative risks of having an event (recurrence of disease, distant metastasis, death) per unit time, along with its 95% confidence interval by applying the Cox proportional hazards method (Cox, 1972) . P values were calculated by the -2log likelihood test. For tPA, in addition, survival curves were computed using the Kaplan-Meier technique (Kaplan and Meier, 1958) . Differences between curves were tested using the log-rank test. Subsequently, independence of prognostic factors was assessed. Therefore, each variable univariately reaching significance (P ≤ 0.05) for one of the end-points was studied in a multivariate Cox proportional hazards model.
RESULTS
Staining results
Staining results obtained by different antibodies against tPA, PAI-1, PAI-2 and uPAR yielded concordant patterns per component with slight variations in intensities. Frequency distributions of the extent of tumour cell staining and of the staining patterns are summarized in Figures 1 and 2 . PAI-1 showed a particular staining pattern; focal staining with participation of junctional/subepidermal tumour nests was seen in the majority of positive cases. 103 of 118 PAI-1-positive lesions had focal tumour cell staining; the junctional/subepidermal region was involved in 100 cases, central tumour parts in 33 cases and the frontal region in 17 cases. For tPA, because of its relation to outcome of disease (see univariate and multivariate analyses), frequencies of the extent of tumour cell positivity are depicted for patient and treatment variables (Table 1) . Representative IHC staining results are shown in Figure 3 .
Spearman's rank correlation coefficients between the extent of tumour cell expression of the different components were weak, although significant between uPAR on the one side and uPA, tPA and PAI-2 on the other side (r = 0.21, 0.17 and 0.16, respectively), and between PAI-2 and tPA (r = 0.34).
Stromal cell staining of macrophages, fibroblast-like cells and endothelial cells was usually very limited; only for PAI-2 and uPAR did more than 10 lesions have stromal cell positivity which exceeded a few cells.
Correlation of new variables with established prognostic clinicopathological variables
The percentage of PAI-1-positive tumour cells was negatively correlated with Breslow thickness (Spearman's rank correlation coefficient = -0.18, P = 0.009). Other significant correlations with Breslow thickness, sex or ulceration were not found, neither for the percentage of positive cells nor for staining pattern.
Prognostic factor analyses
Established prognostic factors As shown in Table 2 , Breslow thickness and microscopic ulceration were important prognostic factors for each of the end-points time to recurrence of disease, time to distant metastasis and overall survival. Sex, site and randomized treatment appeared to be significant for one of these endpoints; subtype, Clark's level, age and elective lymph-node dissection did not reach the significance level in any analysis.
uPA, PAI-1, PAI-2, uPAR Regarding disease-free interval, time to distant metastasis and survival, Cox proportional hazards analysis did not yield significant risk ratios for either percentage of positive tumour cells or the pattern of tumour cell positivity. For PAI-2 and uPAR, the extent of stromal cell positivity was statistically evaluated, since for these components more than ten lesions had substantial stromal cell positivity. However, no groups with differences in prognosis were found. tPA Figure 4 shows the prognostic impact of tPA on the three endpoints relapse-free interval, distant metastasis-free interval and duration of survival. In each of these analyses, patients with lesions having tumour cell positivity in the intermediate category (6-50%) had the worst prognosis, whereas those with the highest percentage of positivity (51-100%) had the best outcome. Table 2 shows the estimated relative risks along with the confidence intervals corresponding to these two groups of patients as compared with the one with the lowest degree of positivity (0-5%). The Cox proportional hazards model showed that if other factors, like Breslow thickness, ulceration, sex, site and allocated treatment, are taken into consideration, the degree of tPA-positivity remained of prognostic importance for the time to distant metastasis (P = 0.012) and for the duration of survival (P = 0.043). In these two analyses, the relative risk estimates of the middle group (6-50% positivity) compared with the 0-5% group equalled 1.9 and the relative risk estimates of the highest group (51-100% positivity) were 0.2 and 0.4 respectively. When another approach was chosen, including in the multivariate model only those variables that were significant in univariate analysis for that specific end-point, the relative risks for tPA-positivity changed slightly. Furthermore, the corresponding P-values decreased, which emphasized even more the prognostic importance of tPA-positivity (results not shown).
DISCUSSION
Former studies on frozen sections of melanomas found components of the PA system to be associated with melanoma progression (Delbaldo et al, 1994; de Vries et al, 1994) . This stimulated us to perform the present study based on primary melanomas of the limb from patients who had been prospectively followed in the framework of an EORTC trial (no. 18832). To that end, 214 routinely processed paraffin-embedded primary melanoma lesions were IHC stained. Differences in uPA, tPA, PAI-1 and PAI-2 expression patterns between former studies (Delbaldo et al, 1994; de Vries et al, 1994) and the present study may be explained by the relatively small number of advanced primary melanomas investigated in the previous studies, which makes results less suitable for generalization. Moreover, the former studies were performed on frozen tissue samples, which are mostly of limited volume, but which have better antigen preservation. Since especially uPA was previously found to be sensitive to fixation time , this should be kept in mind considering the low percentage of uPApositive lesions found in the present study. For PAI-1, we found in an earlier study that this antigen on stromal cells cannot be as reliably unmasked as on tumour cells .
Remarkably, extensive tPA-expression of melanoma cells was related to favourable outcome, whereas for none of the components expression was related to unfavourable outcome of disease, stressing the point that a progression marker is not automatically a prognostic parameter for aggressiveness of disease .
The present study showed best prognosis for the group with abundant tPA tumour cell positivity (51-100%), worse outcome for the limited tPA tumour cell positive group (0-5%), and, strikingly, worst outcome in patients with intermediate tPA tumour cell expression (6-50%). No relation between staining pattern and course of disease was found. tPA tumour cell positivity was an independant prognostic factor for distant metastasis-free interval and overall survival in a multivariate model including other prognostic parameters like Breslow thickness, ulceration, sex, site and treatment.
Attempting to exclude the possibility of a statistical artefact, analyses for tPA were repeated in another small (n = 24) group of European patients that were enrolled in another EORTC trial (no. 18871). This limited study confirmed the results described in this work (results not shown).
The fact that high tPA correlates with good prognosis is not unexpected. This correlation was also found for other types of tumour (Duffy et al, 1998; Jänicke et al, 1991; Yamashita et al, 1993; Bindal et al, 1994; Ganesh et al, 1996; Duggan et al, 1997; Ruppert et al, 1997; Kim et al, 1998a; de Witte et al, 1999) , mostly by using the ELISA technique. Regarding the role of tPA in melanoma invasion, in vitro experiments and animal experimental observations have shown equivocal results (for reviews see de Vries et al, 1996; Ferrier et al, 1998b) . Host protective effects of tPA may be caused by dissolution of the fibrin coating of tumour emboli, as previously discussed by Yamashita et al (1993) . Tumour cell-generated thrombin causes intravascular tumour cells to form microthrombi consisting of tumour cells, platelets and fibrin. These microthrombi secure the arrest of cancer cells in the capillaries and may lead to diapedesis through the capillary wall into the tissues (Rickles and Edwards, 1983; Markus, 1984; Francis et al, 1998; Engelberg, 1999) . Fibrin coating is found to protect tumour cells against the lytic effects of natural killer cells and lymphokine-activated killer cells (Gunji and Gorelik, 1988; Cardinali et al, 1990) . Fibrinolysis by circulating tumour cells, for example by means of fibrin-activated tPA, with consequent dissolution of fibrin deposits around embolized peripheral tumour cells, may decrease the chances of these cells to implant and to form metastases. Another host-protective effect may be the formation of angiostatin, a tumour-derived angiogenesis inhibitor (O'Reilly et al, 1996) . A recent study of our group revealed that angiostatin formation by human melanoma cell lines is basically tPA-dependent (Westphal et al, 2000) .
A tumour metastasis-promoting effect of tPA may be plasminmediated degradation of extracellular matrix. This may facilitate local invasion and release of tumour cells into the circulation. However, several experimental reports indicate that melanoma progression appears to be uPA rather than tPA-related (Quax et al, 1991; Meissauer et al, 1992; Huijzer et al, 1995; Shapiro et al, 1996) . A possible stimulatory effect of tPA on angiogenesis might also enhance metastatic potential (Sato et al, 1993; Hu et al, 1994; Welling et al, 1996) , although no influence of tPA on angiogenesis was found by others (Takei et al, 1995; Lansink et al, 1998; Sakamoto et al, 1998) .
Based on the foregoing, it may be speculated that a shifting balance of metastatic and anti-metastatic effects may act simultaneously with a different predominant effect depending on the level of tPA. A more or less comparable finding was reported by Yamashita et al (1993) , who found that a breast cancer group that remained distant metastasis-free had highest tPA-antigen levels and tPA-activity. Most seriously diseased patients (lung or both lung and bone metastases) had intermediate levels and the group with only bone metastases (bone metastases were explained to often remain localized in the bone for a long time without any further evidence of metastases) had lowest levels.
The apparently complex association between tPA-expression and the outcome of disease in case of melanoma needs to be validated in further series. If the present results are confirmed, it may be considered to offer adjuvant therapy to patients with tPA-based unfavourable prognosis, whereas for patients with high tPAexpressions, and therefore favourable prospects, no additional therapy would be indicated.
